Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs

被引:61
作者
Burnett, Thomas [1 ]
Mozgunov, Pavel [1 ]
Pallmann, Philip [2 ]
Villar, Sofia S. [3 ]
Wheeler, Graham M. [4 ]
Jaki, Thomas [1 ,3 ]
机构
[1] Univ Lancaster, Fylde Coll, Dept Math & Stat, Lancaster LA1 4YF, England
[2] Cardiff Univ, Coll Biomed & Life Sci, Ctr Trials Res, Cardiff, Wales
[3] Univ Cambridge, Cambridge Inst Publ Hlth, MRC Biostat Unit, Sch Clin Med, Forvie Site,Robinson Way,Cambridge Biomed Campus, Cambridge CB2 0SR, England
[4] UCL, Canc Res UK & UCL Canc Trials Ctr, 90 Tottenham Court Rd, London W1T 4TJ, England
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
Novel designs; Innovative trials; Efficient methods; Enrichment designs; Multi-arm multi-stage platform trials; CONTINUAL REASSESSMENT METHOD; SAMPLE-SIZE REESTIMATION; PHASE-I TRIALS; DOSE-FINDING DESIGNS; HYPOTHESES SELECTION; DRUG-COMBINATION; OVERDOSE CONTROL; SEQUENTIAL DESIGNS; TARGETED THERAPY; LUNG-CANCER;
D O I
10.1186/s12916-020-01808-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adaptive designs for clinical trials permit alterations to a study in response to accumulating data in order to make trials more flexible, ethical, and efficient. These benefits are achieved while preserving the integrity and validity of the trial, through the pre-specification and proper adjustment for the possible alterations during the course of the trial. Despite much research in the statistical literature highlighting the potential advantages of adaptive designs over traditional fixed designs, the uptake of such methods in clinical research has been slow. One major reason for this is that different adaptations to trial designs, as well as their advantages and limitations, remain unfamiliar to large parts of the clinical community. The aim of this paper is to clarify where adaptive designs can be used to address specific questions of scientific interest; we introduce the main features of adaptive designs and commonly used terminology, highlighting their utility and pitfalls, and illustrate their use through case studies of adaptive trials ranging from early-phase dose escalation to confirmatory phase III studies.
引用
收藏
页数:21
相关论文
共 204 条
[1]   Adaptive platform trials: definition, design, conduct and reporting considerations The Adaptive Platform Trials Coalition [J].
Angus, Derek C. ;
Alexander, Brian M. ;
Berry, Scott ;
Buxton, Meredith ;
Lewis, Roger ;
Paoloni, Melissa ;
Webb, Steven A. R. ;
Arnold, Steven ;
Barker, Anna ;
Berry, Donald A. ;
Bonten, Marc J. M. ;
Brophy, Mary ;
Butler, Christopher ;
Cloughesy, Timothy F. ;
Derde, Lennie P. G. ;
Esserman, Laura J. ;
Ferguson, Ryan ;
Fiore, Louis ;
Gaffey, Sarah C. ;
Gaziano, J. Michael ;
Giusti, Kathy ;
Goossens, Herman ;
Heritier, Stephane ;
Hyman, Bradley ;
Krams, Michael ;
Larholt, Kay ;
LaVange, Lisa M. ;
Lavori, Philip ;
Lo, Andrew W. ;
London, Alex John ;
Manax, Victoria ;
McArthur, Colin ;
O'Neill, Genevieve ;
Parmigiani, Giovanni ;
Perlmutter, Jane ;
Petzold, Elizabeth A. ;
Ritchie, Craig ;
Rowan, Kathryn M. ;
Seymour, Christopher W. ;
Shapiro, Nathan, I ;
Simeone, Diane M. ;
Smith, Bradley ;
Spellberg, Bradley ;
Stern, Ariel Dora ;
Trippa, Lorenzo ;
Trusheim, Mark ;
Viele, Kert ;
Wen, Patrick Y. ;
Woodcock, Janet .
NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (10) :797-807
[2]   Treatment allocation by minimisation [J].
Altman, DG ;
Bland, JM .
BRITISH MEDICAL JOURNAL, 2005, 330 (7495) :843-843
[3]  
Anderson K, 2009, GSDESIGN R PACK DES
[4]  
[Anonymous], 2013, J STAT SOFTW
[5]  
[Anonymous], 2007, Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design
[6]   Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review [J].
Antoniou, Miranta ;
Jorgensen, Andrea L. ;
Kolamunnage-Dona, Ruwanthi .
PLOS ONE, 2016, 11 (02)
[7]   OPTIMUM BIASED COIN DESIGNS FOR SEQUENTIAL CLINICAL-TRIALS WITH PROGNOSTIC FACTORS [J].
ATKINSON, AC .
BIOMETRIKA, 1982, 69 (01) :61-67
[8]   Optimal sequential designs in phase I studies [J].
Azriel, David .
COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2014, 71 :288-297
[9]  
Babb J, 1998, STAT MED, V17, P1103, DOI 10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO
[10]  
2-9